Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT I PATEL

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1396734547
CMS profile
154032
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,489.90

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,374.85 122
Education $115.05 12

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT I PATEL

NPI 1396734547 · CMS profile ID 154032

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396734547?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT I PATEL, NPI 1396734547, CMS profile ID 154032. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396734547?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AMIT I PATEL, NPI 1396734547, CMS profile ID 154032. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396734547?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AMIT I PATEL, NPI 1396734547, CMS profile ID 154032, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396734547?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $2,489.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.1108/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832764029 CMS
CSL Behring $1.6508/05/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161797 CMS
CSL Behring $1.0908/05/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161803 CMS
CSL Behring $13.3808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161953 CMS
GlaxoSmithKline, LLC. $21.1308/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803160293 CMS
Regeneron Healthcare Solutions, Inc. $20.7008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611657 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.0907/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133527 CMS
Regeneron Healthcare Solutions, Inc. $19.2607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611653 CMS
Regeneron Healthcare Solutions, Inc. $2.0307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611655 CMS
AbbVie Inc. $12.0007/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795528797 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.8507/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133515 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.4407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133521 CMS
GENZYME CORPORATION $13.0107/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843424443 CMS
PFIZER INC. $15.8807/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832750823 CMS
PFIZER INC. $22.0707/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832673313 CMS
Regeneron Healthcare Solutions, Inc. $11.5406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611651 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.9806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133503 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.0806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133509 CMS
Teva Pharmaceuticals USA, Inc. $25.8706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839676719 CMS
kaleo, Inc. $12.2506/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125087 CMS
CSL Behring $1.6506/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161785 CMS
CSL Behring $1.0906/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161791 CMS
CSL Behring $42.2106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161935 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.2106/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133491 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133497 CMS
GlaxoSmithKline, LLC. $8.1906/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802635659 CMS
AstraZeneca Pharmaceuticals LP $11.3806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829652315 CMS
GlaxoSmithKline, LLC. $0.5606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803046259 CMS
Regeneron Healthcare Solutions, Inc. $11.8506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611649 CMS
ALK-Abello, Inc $23.9106/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809209569 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.7706/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133485 CMS
AstraZeneca Pharmaceuticals LP $77.8205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829875953 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.8505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133473 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.0605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133479 CMS
AstraZeneca Pharmaceuticals LP $18.3305/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830112561 CMS
GlaxoSmithKline, LLC. $23.2405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802151807 CMS
Regeneron Healthcare Solutions, Inc. $16.0005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611645 CMS
Regeneron Healthcare Solutions, Inc. $4.1705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611647 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.8005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763339624 CMS
AstraZeneca Pharmaceuticals LP $14.0405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829638129 CMS
Teva Pharmaceuticals USA, Inc. $23.0105/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839676715 CMS
PFIZER INC. $18.9404/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832585225 CMS
GlaxoSmithKline, LLC. $20.8504/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802768965 CMS
CSL Behring $17.9704/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161887 CMS
CSL Behring $8.4104/22/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161755 CMS
GlaxoSmithKline, LLC. $110.5204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803138863 CMS
Regeneron Healthcare Solutions, Inc. $23.8404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611643 CMS
GlaxoSmithKline, LLC. $20.4504/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801911531 CMS
kaleo, Inc. $18.8604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125085 CMS
CSL Behring $34.3604/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161875 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,420.06 81
PY2020 $1,119.39 52
PY2021 $2,489.90 134
PY2022 $3,210.91 147
PY2023 $10,409.03 153
PY2024 $26,999.25 153
PY2025 $39,590.75 162

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $85,737.56 28
PY2024 Principal investigator $49,866.20 25
PY2023 Principal investigator $147,470.33 31
PY2022 Principal investigator $95,184.53 24
PY2021 Principal investigator $152,456.83 19
PY2020 Recipient $2,414.68 17
PY2020 Principal investigator $237,674.19 88
PY2019 Recipient $150.49 1
PY2019 Principal investigator $392,463.61 165

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,368.00 11/12/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104715
Principal investigator 1 GlaxoSmithKline, LLC. $6,264.00 10/15/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103366
Principal investigator 1 GlaxoSmithKline, LLC. $372.00 10/15/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104694
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,765.78 10/08/2025 Non-covered Recipient Entity
INLAND ALLERGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307293
Principal investigator 1 GlaxoSmithKline, LLC. $10,073.00 09/24/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192104700
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,500.00 09/24/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047319
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 09/24/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047321
Principal investigator 1 GlaxoSmithKline, LLC. $62.00 09/03/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103372
Principal investigator 1 GlaxoSmithKline, LLC. $5,247.00 08/20/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104688
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,201.40 08/01/2025 Non-covered Recipient Entity
INLAND ALLERGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307295
Principal investigator 1 GlaxoSmithKline, LLC. $578.70 07/25/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104728
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 07/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047351
Principal investigator 1 GlaxoSmithKline, LLC. $2,557.80 06/16/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103362
Principal investigator 1 GlaxoSmithKline, LLC. $1,104.00 06/06/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104682
Principal investigator 1 GlaxoSmithKline, LLC. $124.00 06/06/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104723
Principal investigator 1 GlaxoSmithKline, LLC. $62.00 05/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103378
Principal investigator 1 GlaxoSmithKline, LLC. $1,580.00 05/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192104707
Principal investigator 1 GlaxoSmithKline, LLC. $124.00 04/25/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103340
Principal investigator 1 GlaxoSmithKline, LLC. $62.00 04/16/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157893
Principal investigator 1 GlaxoSmithKline, LLC. $753.00 04/04/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103350
Principal investigator 1 GlaxoSmithKline, LLC. $1,224.00 04/04/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157905
Principal investigator 1 Incyte Corporation $804.70 03/27/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240539617
Principal investigator 1 GlaxoSmithKline, LLC. $62.00 03/19/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103356
Principal investigator 1 GlaxoSmithKline, LLC. $753.00 03/07/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157889
Principal investigator 1 GlaxoSmithKline, LLC. $1,594.00 02/03/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103345
Principal investigator 1 GlaxoSmithKline, LLC. $399.00 02/03/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157901
Principal investigator 1 Incyte Corporation $6,860.78 01/23/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240539612
Principal investigator 1 GlaxoSmithKline, LLC. $1,561.50 01/13/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157897